<?xml version="1.0" encoding="UTF-8"?>
<supplementary-material content-type="local-data" id="MOESM1">
 <media xlink:href="12916_2019_1411_MOESM1_ESM.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
  <label>Additional file 1:</label>
  <caption>
   <p>This file contains 
    <bold>Appendix A.</bold> country specific data inputs (population sizes, prevalence of hepatitis C among PWID and the general community, and staff costs); 
    <bold>Appendix B.</bold> specific country case studies; 
    <bold>Appendix C.</bold> general settings (results from concentrated, generalised and mixed epidemic settings, with hepatitis C prevalence of 25/50/75% among PWID +/− 1/2/3/5/10/15/20/25/30% among the general community); 
    <bold>Appendix D.</bold> sensitivity analysis (impact of varying harm reduction coverage, vaccine efficacy after treatment, staff costs, vaccine duration of protection, and assumptions about test positivity and progression through the cascade of care); and 
    <bold>Appendix E.</bold> country specific results. (PDF 1989 kb)
   </p>
  </caption>
 </media>
</supplementary-material>
